ClinicalTrials.gg
RecruitingNCT07530185TYCAF-BOXUpdated Nov 18, 2026

Effects of L-Tyrosine and Caffeine on Performance in Elite Boxers

An interventional study of Placebo and L-Tyrosine in Sports Performance, sponsored by Inonu University. Recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Inonu University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Participants will complete six sessions, including one familiarization and baseline session followed by five experimental conditions: control (no supplementation), placebo, L-tyrosine, caffeine, and combined L-tyrosine plus caffeine. The experimental conditions will be performed in a randomized, counterbalanced crossover design with a washout period of at least 72 hours between sessions. Resting physiological and cognitive assessments will be performed during the familiarization session, while biochemical, cognitive, and boxing-specific performance assessments will be conducted before and after each experimental session.

Read the detailed description

Participants will attend six sessions in total. The first session will be used for familiarization and baseline assessments, including anthropometric measurements, resting physiological measurements, and cognitive performance testing. The remaining five sessions will consist of one control condition (no supplementation) and four randomized experimental conditions (placebo, L-tyrosine, caffeine, and combined L-tyrosine plus caffeine) administered in a randomized, counterbalanced crossover design.

Each experimental session will be separated by a washout period of at least 72 hours. During the placebo, L-tyrosine, caffeine, and combined supplementation conditions, the assigned intervention will be administered 60 minutes before exercise. No supplement will be administered during the control condition.

Before and immediately after each experimental session, venous blood samples will be collected to assess brain-derived neurotrophic factor (BDNF) and oxidative stress biomarkers, including total antioxidant status (TAS), total oxidant status (TOS), malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPx). Cognitive performance will be evaluated using the computerized Stroop test, and boxing-specific physical performance will be assessed using a standardized boxing simulation protocol. Heart rate and rating of perceived exertion (RPE) will also be recorded during the exercise protocol.

02

Conditions studied

  • Sports Performance

Keywords

  • L-tyrosine
  • Caffeine
  • Boxing
  • BDNF
  • Cognitive performance
  • Anaerobic performance
03

In context

Lead sponsor

Inonu University is the lead sponsor of 399 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male elite boxers aged ≥18 years At least 8 years of boxing training experience Active participation in national or international competitions Regular training schedule No injury or illness affecting performance

Exclusion criteria

Exclusion Criteria:

Use of nutritional supplements or stimulants within the last 4 weeks Any cardiovascular, metabolic, or neurological disorder Current injury or musculoskeletal limitation Smoking or excessive caffeine intake Failure to comply with study procedures

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants receive placebo condition.

    Dietary Supplement: Placebo

  • Experimental
    L-tyrosine

    Participants receive L-tyrosine condition.

    Dietary Supplement: L-Tyrosine

  • Experimental
    Caffeine

    Participants receive caffeine condition.

    Dietary Supplement: Caffeine

  • Experimental
    Combined

    Participants receive combined supplementation condition.

    Dietary Supplement: L-tyrosine + Caffeine

  • No intervention
    Control

    Participants complete the experimental protocol without receiving placebo or active supplementation. Baseline cognitive, physiological, and physical performance assessments are performed under the control condition.

Interventions

  • Dietary supplementPlacebo

    Placebo solution matched in taste and volume to active supplements.

  • Dietary supplementTyrosineStudies of TyrosineTyrosine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    L-tyrosine at 150 mg/kg body weight administered 60 minutes before exercise.

  • Dietary supplementCaffeine

    Caffeine at 5 mg/kg body weight administered 60 minutes before exercise.

  • Dietary supplementL-tyrosine + Caffeine

    Drug pages: TyrosineStudies of TyrosineTyrosine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CaffeineStudies of CaffeineCaffeine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combined L-tyrosine (150 mg/kg) and caffeine (5 mg/kg) administered 60 minutes before exercise.

06

What researchers measure

Primary outcomes

  1. Stroop Test Performance

    Cognitive performance assessed using the Stroop test, including reaction time and accuracy.

    Time frame: up to 12 weeks

Secondary outcomes

  1. BDNF Levels

    Serum brain-derived neurotrophic factor levels measured before and after exercise.

    Time frame: up to 12 weeks

  2. Oxidative Stress Markers

    Serum levels of total antioxidant status (TAS), total oxidant status (TOS), malondialdehyde (MDA), superoxide dismutase (SOD) activity, and glutathione peroxidase (GPx) activity will be measured.

    Time frame: up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Ataturk University Faculty of Sport Sciences
    Erzurum, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Jan 2027, 1 month after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Sep 2026 → Nov 2026, primary completion Dec 2026 → Jan 2027 and completion Mar 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 15, 2026
StartActual
Nov 15, 2026was Sep 2026
Primary completionEst.
Jan 1, 2027was Dec 2026
CompletionEst.
Jan 1, 2027was Mar 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
Ataturk University Faculty of Sport Sciences is now Recruiting
Nov 18, 2026
Start date
Sep 2026→Nov 15, 2026
Nov 10, 2026
Primary completion
Dec 2026→Jan 1, 2027
Nov 10, 2026
Study completion
Mar 2027→Jan 1, 2027
Nov 10, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    Ataturk University Faculty of Sport Sciences is now Recruiting
    + 1 other change: date precision
  2. Nov 10, 2026
    Start date Sep 2026→Nov 15, 2026
    Primary completion Dec 2026→Jan 1, 2027
    Study completion Mar 2027→Jan 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07530185
Lead sponsor
Inonu University
Collaborators
Ataturk University
Responsible party
Halil UÇAR (Research Assistant and PhD Student, Inonu University) — Principal investigator
First posted
Apr 15, 2026
Start date
Nov 15, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Halil UÇAR
Contact
halil.ucar@inonu.edu.tr
+90 5462921133

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tyrosine · Caffeine

Start the discussion